PUMA BIOTECHNOLOGY, INC. Increase (Decrease) in Accrued Liabilities
PUMA BIOTECHNOLOGY, INC. (PBYI) reported Increase (Decrease) in Accrued Liabilities of $155.00 thousand for the 6-month period ending 2020-06-30, per its 10-Q filed 2020-08-06.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilities · last filed 2020-08-06
- PUMA BIOTECHNOLOGY, INC. increase (decrease) in accrued liabilities for the quarter ending 2020-06-30 was -$279.00K, a 107.03% decline year-over-year.
- PUMA BIOTECHNOLOGY, INC. increase (decrease) in accrued liabilities for the quarter ending 2020-03-31 was $434.00K, a 98.18% decline year-over-year.
- PUMA BIOTECHNOLOGY, INC. increase (decrease) in accrued liabilities for the quarter ending 2019-12-31 was -$7.74M, a 257.53% decline year-over-year.
- PUMA BIOTECHNOLOGY, INC. increase (decrease) in accrued liabilities for the quarter ending 2019-09-30 was $2.52M, a 673.01% increase year-over-year.
- PUMA BIOTECHNOLOGY, INC. increase (decrease) in accrued liabilities for fiscal 2019 was $22.60M, a 43.19% increase from fiscal 2018.
- PUMA BIOTECHNOLOGY, INC. increase (decrease) in accrued liabilities for fiscal 2018 was $15.78M, a 19.37% increase from fiscal 2017.
- PUMA BIOTECHNOLOGY, INC. increase (decrease) in accrued liabilities for fiscal 2017 was $13.22M, a 374.42% increase from fiscal 2016.
- PUMA BIOTECHNOLOGY, INC. increase (decrease) in accrued liabilities for fiscal 2016 was $2.79M.
| Period end | Increase (Decrease) in Accrued Liabilities 3 month | Increase (Decrease) in Accrued Liabilities 6 month | Increase (Decrease) in Accrued Liabilities 9 month | Increase (Decrease) in Accrued Liabilities 12 month | Increase (Decrease) in Accrued Liabilities 27 month | Increase (Decrease) in Accrued Liabilities 30 month | Increase (Decrease) in Accrued Liabilities 33 month | Increase (Decrease) in Accrued Liabilities 36 month | Increase (Decrease) in Accrued Liabilities 39 month | Increase (Decrease) in Accrued Liabilities 42 month | Increase (Decrease) in Accrued Liabilities 45 month | Increase (Decrease) in Accrued Liabilities 48 month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2020-06-30 | -$279.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $155.00K 10-Q · filed 2020-08-06 | -$7.59M derived: sum of 3 quarters · filed 2020-08-06 | -$5.07M derived: sum of 4 quarters · filed 2020-08-06 | ||||||||
| 2020-03-31 | $434.00K 10-Q · filed 2020-05-07 | -$7.31M derived: sum of 2 quarters · filed 2020-05-07 | -$4.79M derived: sum of 3 quarters · filed 2020-05-07 | -$817.00K derived: sum of 4 quarters · filed 2020-08-06 | ||||||||
| 2019-12-31 | -$7.74M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-28 | -$5.22M derived: sum of 2 quarters · filed 2020-02-28 | -$1.25M derived: sum of 3 quarters · filed 2020-08-06 | $22.60M 10-K · filed 2020-02-28 | ||||||||
| 2019-09-30 | $2.52M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | $6.49M derived: sum of 2 quarters · filed 2020-08-06 | $30.34M 10-Q · filed 2019-11-07 | $35.25M derived: sum of 4 quarters · filed 2020-08-06 | ||||||||
| 2019-06-30 | $3.97M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $27.82M 10-Q · filed 2020-08-06 | $32.73M derived: sum of 3 quarters · filed 2020-08-06 | $33.06M derived: sum of 4 quarters · filed 2020-08-06 | ||||||||
| 2019-03-31 | $23.85M 10-Q · filed 2020-05-07 | $28.76M derived: sum of 2 quarters · filed 2020-05-07 | $29.09M derived: sum of 3 quarters · filed 2020-05-07 | $35.72M derived: sum of 4 quarters · filed 2020-05-07 | ||||||||
| 2018-12-31 | $4.91M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-28 | $5.24M derived: sum of 2 quarters · filed 2020-02-28 | $11.87M derived: sum of 3 quarters · filed 2020-02-28 | $15.78M 10-K · filed 2020-02-28 | ||||||||
| 2018-09-30 | $326.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | $6.96M derived: sum of 2 quarters · filed 2019-11-07 | $10.87M 10-Q · filed 2019-11-07 | $11.91M derived: sum of 4 quarters · filed 2020-02-28 | ||||||||
| 2018-06-30 | $6.63M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-09 | $10.54M 10-Q · filed 2019-08-09 | $11.58M derived: sum of 3 quarters · filed 2020-02-28 | $18.62M derived: sum of 4 quarters · filed 2020-02-28 | ||||||||
| 2018-03-31 | $3.91M 10-Q · filed 2019-05-10 | $4.95M derived: sum of 2 quarters · filed 2020-02-28 | $11.98M derived: sum of 3 quarters · filed 2020-02-28 | $14.80M derived: sum of 4 quarters · filed 2020-02-28 | ||||||||
| 2017-12-31 | $1.04M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-28 | $8.07M derived: sum of 2 quarters · filed 2020-02-28 | $10.89M derived: sum of 3 quarters · filed 2020-02-28 | $13.22M 10-K · filed 2020-02-28 | ||||||||
| 2017-09-30 | $7.03M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-05 | $9.85M derived: sum of 2 quarters · filed 2018-11-05 | $12.18M 10-Q · filed 2018-11-05 | $12.89M derived: sum of 4 quarters · filed 2019-03-01 | ||||||||
| 2017-06-30 | $2.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | $5.15M 10-Q · filed 2018-08-09 | $5.85M derived: sum of 3 quarters · filed 2019-03-01 | $8.23M derived: sum of 4 quarters · filed 2019-03-01 | ||||||||
| 2017-03-31 | $2.33M 10-Q · filed 2018-05-10 | $3.04M derived: sum of 2 quarters · filed 2019-03-01 | $5.42M derived: sum of 3 quarters · filed 2019-03-01 | $5.69M derived: sum of 4 quarters · filed 2019-03-01 | ||||||||
| 2016-12-31 | $705.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01 | $3.08M derived: sum of 2 quarters · filed 2019-03-01 | $3.36M derived: sum of 3 quarters · filed 2019-03-01 | $2.79M 10-K · filed 2019-03-01 | ||||||||
| 2016-09-30 | $2.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | $2.65M derived: sum of 2 quarters · filed 2017-11-09 | $2.08M 10-Q · filed 2017-11-09 | $1.17M derived: sum of 4 quarters · filed 2018-03-09 | ||||||||
| 2016-06-30 | $276.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | -$295.00K 10-Q · filed 2017-08-09 | -$1.20M derived: sum of 3 quarters · filed 2018-03-09 | -$1.31M derived: sum of 4 quarters · filed 2018-03-09 | ||||||||
| 2016-03-31 | -$571.00K 10-Q · filed 2017-05-10 | -$1.48M derived: sum of 2 quarters · filed 2018-03-09 | -$1.59M derived: sum of 3 quarters · filed 2018-03-09 | $599.00K derived: sum of 4 quarters · filed 2018-03-09 | ||||||||
| 2015-12-31 | -$909.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-09 | -$1.02M derived: sum of 2 quarters · filed 2018-03-09 | $1.17M derived: sum of 3 quarters · filed 2018-03-09 | -$14.80M 10-K · filed 2018-03-09 | ||||||||
| 2015-09-30 | -$107.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | $2.08M derived: sum of 2 quarters · filed 2016-11-09 | -$13.90M 10-Q · filed 2016-11-09 | $4.64M derived: sum of 4 quarters · filed 2017-03-01 | ||||||||
| 2015-06-30 | $2.19M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | -$13.79M 10-Q · filed 2016-08-09 | $4.74M derived: sum of 3 quarters · filed 2017-03-01 | $6.52M derived: sum of 4 quarters · filed 2017-03-01 | ||||||||
| 2015-03-31 | -$15.97M 10-Q · filed 2016-05-10 | $2.56M derived: sum of 2 quarters · filed 2017-03-01 | $4.33M derived: sum of 3 quarters · filed 2017-03-01 | $8.42M derived: sum of 4 quarters · filed 2017-03-01 | ||||||||
| 2014-12-31 | $18.53M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01 | $20.31M derived: sum of 2 quarters · filed 2017-03-01 | $24.39M derived: sum of 3 quarters · filed 2017-03-01 | $20.86M 10-K · filed 2017-03-01 | ||||||||
| 2014-09-30 | $1.78M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09 | $5.86M derived: sum of 2 quarters · filed 2015-11-09 | $2.33M 10-Q · filed 2015-11-09 | $1.42M derived: sum of 4 quarters · filed 2016-02-29 | $10.91M 10-Q · filed 2014-11-10 | |||||||
| 2014-06-30 | $4.08M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-10 | $556.00K 10-Q · filed 2015-08-10 | -$361.00K derived: sum of 3 quarters · filed 2016-02-29 | -$3.06M derived: sum of 4 quarters · filed 2016-02-29 | $9.13M 10-Q · filed 2014-08-11 | |||||||
| 2014-03-31 | -$3.53M 10-Q · filed 2015-05-11 | -$4.45M derived: sum of 2 quarters · filed 2016-02-29 | -$7.15M derived: sum of 3 quarters · filed 2016-02-29 | -$9.69M derived: sum of 4 quarters · filed 2016-02-29 | $5.05M 10-Q · filed 2014-05-12 | |||||||
| 2013-12-31 | -$917.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | -$3.62M derived: sum of 2 quarters · filed 2016-02-29 | -$6.16M derived: sum of 3 quarters · filed 2016-02-29 | -$12.64M 10-K · filed 2016-02-29 | $8.58M 10-K · filed 2014-03-03 | |||||||
| 2013-09-30 | -$2.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-10 | -$5.25M derived: sum of 2 quarters · filed 2014-11-10 | -$11.72M 10-Q · filed 2014-11-10 | -$16.15M derived: sum of 4 quarters · filed 2015-03-02 | $9.50M 10-Q · filed 2013-11-12 | |||||||
| 2013-06-30 | -$2.54M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-11 | -$9.02M 10-Q · filed 2014-08-11 | -$13.44M derived: sum of 3 quarters · filed 2015-03-02 | -$933.00K derived: sum of 4 quarters · filed 2015-03-02 | $12.20M 10-Q · filed 2013-08-06 | |||||||
| 2013-03-31 | -$6.48M 10-Q · filed 2014-05-12 | -$10.90M derived: sum of 2 quarters · filed 2015-03-02 | $1.61M derived: sum of 3 quarters · filed 2015-03-02 | $5.91M derived: sum of 4 quarters · filed 2015-03-02 | $14.74M 10-Q · filed 2013-05-09 | |||||||
| 2012-12-31 | -$4.42M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-02 | $8.09M derived: sum of 2 quarters · filed 2015-03-02 | $12.39M derived: sum of 3 quarters · filed 2015-03-02 | $20.72M 10-K · filed 2015-03-02 | $21.22M 10-K · filed 2013-04-01 | |||||||
| 2012-09-30 | $12.51M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-12 | $16.81M derived: sum of 2 quarters · filed 2013-11-12 | $25.14M 10-Q · filed 2013-11-12 | |||||||||
| 2012-06-30 | $4.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-06 | $12.63M 10-Q · filed 2013-08-06 | ||||||||||
| 2012-03-31 | $8.33M 10-Q · filed 2013-05-09 | |||||||||||
| 2011-12-31 | $500.00K 10-K · filed 2014-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |